55 completed, 17 unknown, 5 active not recruiting, 5 terminated. 31 Phase 1, 19 Phase 2, 11 Phase 4, 10 Phase 3, 9 Not applicable.
Follow Malaria,Falciparum: new trials by email Literature Review of Malaria,Falciparum trials Research Report on Malaria,Falciparum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M R21, RH5.1, R78C - Malaria,Falciparum | Phase 2 | Active not recruiting | University of Oxford | 360 | 2025-12-15 | 2026-10-21 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) R21, RH5.1, R78C - Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 56 | 2025-09-15 | 2026-10-21 |
| Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso SUM-101 - Malaria,Falciparum | Phase 1 | Completed | European Vaccine Initiative | 39 | 2025-08-01 | 2026-09-11 |
| An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause) - Malaria,Falciparum, Morality | Recruiting | Serum Institute of India Pvt. Ltd. | 2308 | 2025-06-16 | 2025-08-13 | |
| Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge) CHMI with 3D7 malaria - Malaria,Falciparum | Phase 1 | Not yet recruiting | Leiden University Medical Center | 14 | 2025-03-01 | 2024-12-27 |
| Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine - Malaria,Falciparum, Anemia in Children | Phase 4 | Completed | Liverpool School of Tropical Medicine | 788 | 2024-10-14 | 2026-07-30 |
| Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants MMV371 LAI, Placebo for MMV371 - Malaria,Falciparum | Phase 1 | Completed | Medicines for Malaria Venture | 32 | 2024-08-27 | 2026-05-05 |
| Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali TB31F, Normal saline - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 167 | 2024-07-12 | 2026-01-22 |
| Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children Malaria,Falciparum | Unknown | Malaria Consortium | 300 | 2024-06-12 | 2024-07-29 | |
| The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children Mosquirixs, artemether-lumefantrine - Malaria,Falciparum | Phase 4 | Unknown | Kamuzu University of Health Sciences | 5400 | 2024-06-01 | 2024-05-21 |
| Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique Sulfadoxine/pyrimethamine plus amodiaquine - Malaria,Falciparum, Chemoprevention | Phase 4 | Unknown | Malaria Consortium | 1000 | 2024-03-26 | 2024-03-29 |
| A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™ R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3) - Malaria,Falciparum | Phase 1 | Completed | University of Oxford | 36 | 2024-03-25 | 2026-10-21 |
| Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda. Artemisia afra or Annua 10g oral infusion/tea per day for 14 days - Malaria,Falciparum | Phase 2 | Not yet recruiting | King Faisal Hospital Rwanda | 125 | 2024-03-01 | 2023-10-17 |
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT), Artemether-lumefantrine (AL) - Malaria,Falciparum, Malaria in Pregnancy | Phase 4 | Active not recruiting | Duke University | 2174 | 2023-11-06 | 2026-05-07 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum MMV367 3mg, P. falciparum IBSM infection, MMV367 5mg - Infections, Vector Borne Diseases | Phase 1 | Completed | Medicines for Malaria Venture | 12 | 2023-08-01 | 2025-12-10 |
| CHILD (Child Health and Infection With Low Density) Malaria Active case detection using molecular testing (ACDm), Passive case detection using molecular testing (PCDm), Control (standard of care) - Malaria,Falciparum, Malaria | Not applicable | Completed | University of California, San Francisco | 600 | 2023-07-18 | 2026-01-29 |
| Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC) Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT, Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT, Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT - Malaria, Malaria,Falciparum | Not applicable | Completed | London School of Hygiene and Tropical Medicine | 2978 | 2023-07-13 | 2025-07-04 |
| A Study to Compare Two Dosing Regimens for a New Malaria Vaccine Matrix M with RH5.1 - Malaria, Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 24 | 2023-06-06 | 2024-10-04 |
| A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 390 | 2023-04-03 | 2026-10-21 |
Showing 20 of 87. Sign in to see all of them.
Malaria, Falciparum (87) · Malaria (46) · Parasitic Diseases (6) · Infections (5) · Anemia (4) · Protozoan Infections (4) · Malaria, Vivax (3) · Parasitemia (3) · Vector Borne Diseases (3) · Asymptomatic Infections (2) · Malnutrition (2) · Sepsis (2) · Acute Kidney Injury (1) · Ancylostomiasis (1) · Bacterial Infections (1)
Mosquito-Borne Diseases (87) · Vector Borne Diseases (84) · Protozoan Infections (83) · Infections (82) · Parasitic Diseases (81) · Malaria (41) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (9) · Hemic and Lymphatic Diseases (5) · Hematologic Diseases (4) · Inflammation (4) · Systemic Inflammatory Response Syndrome (4) · Disease Attributes (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3)
Artemether, Lumefantrine Drug Combination (14) · Primaquine (10) · Matrix-M (8) · fanasil, pyrimethamine drug combination (5) · Amodiaquine (4) · piperaquine (4) · Artesunate (3) · Chloroquine (3) · Rabies Vaccines (3) · Saline Solution (3) · amodiaquine, artesunate drug combination (3) · artenimol (3) · pyronaridine (3) · pyronaridine tetraphosphate, artesunate drug combination (3) · Aluminum Hydroxide (2)
University of Oxford (15) · London School of Hygiene and Tropical Medicine (8) · Radboud University Medical Center (7) · Medicines for Malaria Venture (6) · Sanaria Inc. (3) · University of California, San Francisco (3) · University of Maryland, Baltimore (3) · Duke University (2) · Institute of Tropical Medicine, Belgium (2) · Leiden University Medical Center (2) · Malaria Consortium (2) · Research Institute for Tropical Medicine, Philippines (2) · Shin Poong Pharmaceutical Co. Ltd. (2) · Vac4All (2) · Centre MURAZ/Institut National de Santé Publique (1)
Burkina Faso (13) · Mali (11) · Tanzania (10) · Netherlands (7) · United Kingdom (7) · Kenya (6) · Democratic Republic of the Congo (5) · Cameroon (4) · Malawi (4) · Uganda (3) · United States (3) · Australia (2) · Belgium (2) · Côte d’Ivoire (2) · Mozambique (2)
Alassane Dicko (2) · Alassane Dicko, Professor (2) · Angela Minassian (2) · Jean Bosco Ouedraogo, Professor (2) · Lauren Cohee, MD MS (2) · Patrick Duffy, MD (2) · Aaron Samuels, MD (1) · Adrian Hill (1) · Alfred Tiono, PhD, MD (1) · Ally Olotu (1) · Ally Olotu, MD, PhD (1) · Andreas Martensson, PhD (1) · Angela M Minassian (1)
PMID 41176969, PMID 26654101, PMID 29061746, PMID 30488945, PMID 32239171, PMID 32324850, PMID 32382685, PMID 32434846, PMID 32576258, PMID 32664948, PMID 32933955, PMID 33253198, PMID 33289099, PMID 33767384, PMID 33964223, PMID 33983371, PMID 34129601, PMID 34166393, PMID 34432975, PMID 34781256, PMID 34894221, PMID 35028628, PMID 35189818, PMID 35189830, PMID 35193608, PMID 35290461, PMID 35820756, PMID 35945599, PMID 35963275, PMID 36036611, PMID 36087586, PMID 36203149, PMID 36215323, PMID 36578806, PMID 36877726, PMID 37024868, PMID 37221018, PMID 37419638, PMID 37474234, PMID 37625434, PMID 37980467, PMID 38194272, PMID 38252481, PMID 38418982, PMID 38479748, PMID 38538037, PMID 38649867, PMID 38705163, PMID 38811947, PMID 38813551
2017 (1), 2019 (1), R01HL134211 (1), U01AI155315 (1), U01AI162463 (1), U19AI089683 (1), U44AI167783 (1)